We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
26
Illumina
ILMN
$28.2B
$54.3M 1.05%
204,560
-23,314
-10% -$6.52M
ARVN icon
27
Arvinas
ARVN
$517M
$51.2M 0.99%
1,269,303
+27,400
+2% +$1.28M
BSX icon
28
Boston Scientific
BSX
$65.4B
$50.3M 0.98%
1,541,225
-37,396
-2% -$1.46M
CNC icon
29
Centene
CNC
$32.8B
$48.1M 0.93%
810,270
+69,659
+9% +$4.23M
BAX icon
30
Baxter International
BAX
$11.7B
$48.1M 0.93%
591,921
+52,246
+10% +$4.51M
DHR icon
31
Danaher
DHR
$144B
$47.8M 0.93%
389,703
-23,814
-6% -$3.21M
AKCA
32
DELISTED
Akcea Therapeutics Inc
AKCA
$45.8M 0.89%
3,204,244
+41,601
+1% +$683K
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$44.6M 0.87%
708,976
-6,200
-0.9% -$557K
EW icon
34
Edwards Lifesciences
EW
$49.4B
$44.1M 0.86%
701,895
+93,666
+15% +$6.75M
CRL icon
35
Charles River Laboratories
CRL
$10.8B
$41.9M 0.81%
331,623
+48,525
+17% +$7.28M
SAGE
36
DELISTED
Sage Therapeutics
SAGE
$40.7M 0.79%
1,418,104
+109,250
+8% +$6.33M
MTEM
37
DELISTED
Molecular Templates, Inc.
MTEM
$38.7M 0.75%
194,043
+107,664
+125% +$23.6M
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$15.5B
$37M 0.72%
371,337
-9,966
-3% -$1.29M
MYOV
39
DELISTED
Myovant Sciences Ltd.
MYOV
$36.4M 0.71%
4,815,109
– –
MGNX icon
40
MacroGenics
MGNX
$285M
$35.6M 0.69%
6,119,150
+245,794
+4% +$2.23M
ALGN icon
41
Align Technology
ALGN
$12.7B
$35.3M 0.69%
203,076
-75,627
-27% -$18.1M
FATE icon
42
Fate Therapeutics
FATE
$324M
$34.7M 0.67%
1,563,200
+1,480,400
+1,788% +$37.4M
CRSP icon
43
CRISPR Therapeutics
CRSP
$4.71B
$33.9M 0.66%
800,462
+70,000
+10% +$3.61M
BDTX icon
44
Black Diamond Therapeutics
BDTX
$103M
$33.2M 0.64%
+1,330,000
New +$40.5M
SRRK icon
45
Scholar Rock
SRRK
$6.33B
$32.9M 0.64%
2,715,106
+80,640
+3% +$1.08M
TDOC icon
46
Teladoc Health
TDOC
$1.7B
$31.2M 0.6%
201,235
-548,810
-73% -$63.8M
HRC
47
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$29.7M 0.58%
295,479
+58,193
+25% +$6.03M
SYK icon
48
Stryker
SYK
$123B
$28.8M 0.56%
172,713
+11,458
+7% +$2.24M
CDNA icon
49
CareDx
CDNA
$2.05B
$27.9M 0.54%
1,277,051
+100,321
+9% +$2.25M
DXCM icon
50
DexCom
DXCM
$29.6B
$27.3M 0.53%
405,312
+91,412
+29% +$5.69M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.